Source:Current Problems in Cancer
Author(s): Naoka Murakami, Shveta Motwani, Leonardo V. Riella
Immune checkpoint inhibitors have been approved for a variety of cancer species. Renal complications in use of these agents are not very common compared with other immune related adverse events (irAE). However, it is crucial for physicians to recognize and manage renal manifestations of irAE. In this review, we will summarize the up-to-date knowledge of the clinical presentation, pathological features and management of renal irAE. In addition, we will discuss the safety of immune checkpoint inhibitors in patients with chronic kidney disease as well as in kidney transplant recipients.
http://ift.tt/2hPbvey
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου